In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

Approved KRAS inhibitors Lumakras and Krazati may soon face more competition as second-generation G12C inhibitors and other KRAS approaches advance.

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.